{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:21:25Z","timestamp":1790986885761,"version":"4.1.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["HORM CANC"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1007\/s12672-011-0090-6","type":"journal-article","created":{"date-parts":[[2011,12,14]],"date-time":"2011-12-14T15:39:36Z","timestamp":1323877176000},"page":"385-392","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Targeted Therapies for Adrenocortical Carcinoma: IGF and Beyond"],"prefix":"10.1007","volume":"2","author":[{"given":"Michael J.","family":"Demeure","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly J.","family":"Bussey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence S.","family":"Kirschner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,12,15]]},"reference":[{"key":"90_CR1","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1038\/nrc2536","volume":"8","author":"M Pollak","year":"2008","unstructured":"Pollak M (2008) Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8:915\u2013928","journal-title":"Nat Rev Cancer"},{"key":"90_CR2","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1210\/jc.2008-1456","volume":"94","author":"FM Barlaskar","year":"2009","unstructured":"Barlaskar FM, Spalding AC, Heaton JH et al (2009) Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma. J Clin Endocrinol Metab 94:204\u2013212","journal-title":"J Clin Endocrinol Metab"},{"key":"90_CR3","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/nrc1913","volume":"6","author":"K Imai","year":"2006","unstructured":"Imai K, Takaoka A (2006) Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer 6:714\u2013727","journal-title":"Nat Rev Cancer"},{"key":"90_CR4","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1158\/1535-7163.MCT-08-0265","volume":"7","author":"J Rodon","year":"2008","unstructured":"Rodon J, DeSantos V, Ferry RJ, Kurzrock R (2008) Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials. Mol Cancer Ther 7:2575\u20132588","journal-title":"Mol Cancer Ther"},{"key":"90_CR5","doi-asserted-by":"publisher","first-page":"8322","DOI":"10.1158\/0008-5472.CAN-07-6720","volume":"68","author":"E Buck","year":"2008","unstructured":"Buck E, Eyzaguirre A, Rosenfeld-Franklin M et al (2008) Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors. Cancer Res 68:8322\u20138332","journal-title":"Cancer Res"},{"key":"90_CR6","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1177\/1534735403259152","volume":"2","author":"DB Boyd","year":"2003","unstructured":"Boyd DB (2003) Insulin and cancer. Integr Cancer Ther 2:315\u2013329","journal-title":"Integr Cancer Ther"},{"key":"90_CR7","doi-asserted-by":"crossref","unstructured":"Dastrup E, Demeure MJ, Bussey KJ. Adrenocortical carcinoma cell lines are sensitive to compounds targeting the G2\/M transition [abstract]. In Proceedings of the 101st Annual Meeting of the American Association for Cancer Research. Washington. AACR; 2010:Abstract nr 3672","DOI":"10.1158\/1538-7445.AM10-3672"},{"key":"90_CR8","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nrc2656","volume":"9","author":"J Baselga","year":"2009","unstructured":"Baselga J, Swain SM (2009) Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 9:463\u2013475","journal-title":"Nat Rev Cancer"},{"key":"90_CR9","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/0046-8177(90)90227-V","volume":"21","author":"T Kamio","year":"1990","unstructured":"Kamio T, Shigematsu K, Sou H, Kawai K, Tsuchiyama H (1990) Immunohistochemical expression of epidermal growth factor receptors in human adrenocortical carcinoma. Hum Pathol 21:277\u2013282","journal-title":"Hum Pathol"},{"key":"90_CR10","first-page":"741","volume":"7","author":"H Sasano","year":"1994","unstructured":"Sasano H, Suzuki T, Shizawa S, Kato K, Nagura H (1994) Transforming growth factor alpha, epidermal growth factor, and epidermal growth factor receptor expression in normal and diseased human adrenal cortex by immunohistochemistry and in situ hybridization. Mod Pathol 7:741\u2013746","journal-title":"Mod Pathol"},{"key":"90_CR11","doi-asserted-by":"crossref","first-page":"15527","DOI":"10.1200\/jco.2007.25.18_suppl.15527","volume":"25","author":"V Samnotra","year":"2007","unstructured":"Samnotra V, Vassilopoulou-Sellin R, Fojo A et al (2007) A phase II trial of gefitinib monotherapy in patients with unresectable adrenocortical carcinoma (ACC). J Clin Oncol 25:15527","journal-title":"J Clin Oncol"},{"key":"90_CR12","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1210\/jc.2007-2564","volume":"93","author":"M Quinkler","year":"2008","unstructured":"Quinkler M, Hahner S, Wortmann S et al (2008) Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine. J Clin Endocrinol Metab 93:2057\u20132062","journal-title":"J Clin Endocrinol Metab"},{"key":"90_CR13","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1210\/jc.2004-1075","volume":"90","author":"F de Fraipont","year":"2005","unstructured":"de Fraipont F, El Atifi M, Cherradi N et al (2005) Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic acid microarrays identifies several candidate genes as markers of malignancy. J Clin Endocrinol Metab 90:1819\u20131829","journal-title":"J Clin Endocrinol Metab"},{"key":"90_CR14","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S0002-9440(10)63846-1","volume":"162","author":"TJ Giordano","year":"2003","unstructured":"Giordano TJ, Thomas DG, Kuick R et al (2003) Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. Am J Pathol 162:521\u2013531","journal-title":"Am J Pathol"},{"key":"90_CR15","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1530\/eje.1.02116","volume":"154","author":"EP Slater","year":"2006","unstructured":"Slater EP, Diehl SM, Langer P et al (2006) Analysis by cDNA microarrays of gene expression patterns of human adrenocortical tumors. Eur J Endocrinol 154:587\u2013598","journal-title":"Eur J Endocrinol"},{"key":"90_CR16","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1158\/0008-5472.CAN-06-3767","volume":"67","author":"AN West","year":"2007","unstructured":"West AN, Neale GA, Pounds S et al (2007) Gene expression profiling of childhood adrenocortical tumors. Cancer Res 67:600\u2013608","journal-title":"Cancer Res"},{"key":"90_CR17","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/nrc2780","volume":"10","author":"N Turner","year":"2010","unstructured":"Turner N, Grose R (2010) Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 10:116\u2013129","journal-title":"Nat Rev Cancer"},{"key":"90_CR18","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.1182\/blood-2004-10-3913","volume":"105","author":"S Trudel","year":"2005","unstructured":"Trudel S, Li ZH, Wei E et al (2005) CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood 105:2941\u20132948","journal-title":"Blood"},{"key":"90_CR19","doi-asserted-by":"publisher","first-page":"4908","DOI":"10.1158\/1078-0432.CCR-06-0957","volume":"12","author":"X Xin","year":"2006","unstructured":"Xin X, Abrams TJ, Hollenbach PW et al (2006) CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in mice. Clin Cancer Res 12:4908\u20134915","journal-title":"Clin Cancer Res"},{"key":"90_CR20","doi-asserted-by":"publisher","first-page":"3729","DOI":"10.1182\/blood-2007-02-074286","volume":"110","author":"A Chase","year":"2007","unstructured":"Chase A, Grand FH, Cross NC (2007) Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome. Blood 110:3729\u20133734","journal-title":"Blood"},{"key":"90_CR21","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s11060-009-9885-5","volume":"94","author":"W Loilome","year":"2009","unstructured":"Loilome W, Joshi AD, ap Rhys CM et al (2009) Glioblastoma cell growth is suppressed by disruption of fibroblast growth factor pathway signaling. J Neurooncol 94:359\u2013366","journal-title":"J Neurooncol"},{"key":"90_CR22","unstructured":"Zhang H, Masuoka L, Baker K et al (2007) FP-1039 (FGFR1:Fc), A Soluble FGFR1 receptor antagonist, inhibits tumor growth and angiogenesis. In AACR-NCI-EORTC International Conference Molecular Targets and Cancer Therapeutics Discovery, Biology and Clinical Applications. San Francisco, CA.; 2007"},{"key":"90_CR23","doi-asserted-by":"crossref","first-page":"A103","DOI":"10.1186\/1476-4598-8-103","volume":"8","author":"A Tolcher","year":"2009","unstructured":"Tolcher A, Papadopoulos K, Agnew J et al (2009) Preliminary results of a phase 1 study of FP-1039 (FGFR1:Fc), a novel antagonist of multiple fibroblast growth factor (FGF) ligands, in patients with advanced malignancies. Mol Cancer Ther 8:A103","journal-title":"Mol Cancer Ther"},{"key":"90_CR24","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/0092-8674(93)90330-S","volume":"75","author":"FS Leach","year":"1993","unstructured":"Leach FS, Nicolaides NC, Papadopoulos N et al (1993) Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 75:1215\u20131225","journal-title":"Cell"},{"key":"90_CR25","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/0092-8674(93)90546-3","volume":"75","author":"R Fishel","year":"1993","unstructured":"Fishel R, Lescoe MK, Rao MR et al (1993) The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 75:1027\u20131038","journal-title":"Cell"},{"key":"90_CR26","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/nature03319","volume":"434","author":"T Reya","year":"2005","unstructured":"Reya T, Clevers H (2005) Wnt signalling in stem cells and cancer. Nature 434:843\u2013850","journal-title":"Nature"},{"key":"90_CR27","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1365-2265.2007.03033.x","volume":"68","author":"M Tadjine","year":"2008","unstructured":"Tadjine M, Lampron A, Ouadi L, Bourdeau I (2008) Frequent mutations of beta-catenin gene in sporadic secreting adrenocortical adenomas. Clin Endocrinol (Oxf) 68:264\u2013270","journal-title":"Clin Endocrinol (Oxf)"},{"key":"90_CR28","doi-asserted-by":"publisher","first-page":"4135","DOI":"10.1210\/jc.2008-0631","volume":"93","author":"S Gaujoux","year":"2008","unstructured":"Gaujoux S, Tissier F, Groussin L et al (2008) Wnt\/beta-catenin and 3\u2032,5\u2032-cyclic adenosine 5\u2032-monophosphate\/protein kinase A signaling pathways alterations and somatic beta-catenin gene mutations in the progression of adrenocortical tumors. J Clin Endocrinol Metab 93:4135\u20134140","journal-title":"J Clin Endocrinol Metab"},{"key":"90_CR29","doi-asserted-by":"crossref","first-page":"7622","DOI":"10.1158\/0008-5472.CAN-05-0593","volume":"65","author":"F Tissier","year":"2005","unstructured":"Tissier F, Cavard C, Groussin L et al (2005) Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. Cancer Res 65:7622\u20137627","journal-title":"Cancer Res"},{"key":"90_CR30","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1007\/BF00220544","volume":"89","author":"M Seki","year":"1992","unstructured":"Seki M, Tanaka K, Kikuchi-Yanoshita R et al (1992) Loss of normal allele of the APC gene in an adrenocortical carcinoma from a patient with familial adenomatous polyposis. Hum Genet 89:298\u2013300","journal-title":"Hum Genet"},{"key":"90_CR31","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1200\/JCO.2008.18.5678","volume":"27","author":"A de Reynies","year":"2009","unstructured":"de Reynies A, Assie G, Rickman DS et al (2009) Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. J Clin Oncol 27:1108\u20131115","journal-title":"J Clin Oncol"},{"key":"90_CR32","doi-asserted-by":"crossref","first-page":"563","DOI":"10.18632\/oncotarget.191","volume":"1","author":"JC Curtin","year":"2010","unstructured":"Curtin JC, Lorenzi MV (2010) Drug discovery approaches to target Wnt signaling in cancer stem cells. Oncotarget 1:563\u2013577","journal-title":"Oncotarget"},{"key":"90_CR33","doi-asserted-by":"crossref","unstructured":"Cha JY, Jung J-E, Lee K-H et al (2010) Anti-tumor activity of novel small molecule Wnt signaling inhibitor, CWP232291, in multiple myeloma. In 52nd American Society for Hematology Annual Meeting. Orlando, FL:3038","DOI":"10.1182\/blood.V116.21.3038.3038"},{"key":"90_CR34","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1093\/jnci\/djp084","volume":"101","author":"K Garber","year":"2009","unstructured":"Garber K (2009) Drugging the Wnt pathway: problems and progress. J Natl Cancer Inst 101:548\u2013550","journal-title":"J Natl Cancer Inst"},{"key":"90_CR35","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/1476-4598-9-75","volume":"9","author":"JR Sierra","year":"2010","unstructured":"Sierra JR, Cepero V, Giordano S (2010) Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy. Mol Cancer 9:75","journal-title":"Mol Cancer"},{"key":"90_CR36","first-page":"1107","volume":"33","author":"MP Cunningham","year":"2008","unstructured":"Cunningham MP, Thomas H, Marks C et al (2008) Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells. Int J Oncol 33:1107\u20131113","journal-title":"Int J Oncol"},{"key":"90_CR37","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s10911-008-9107-3","volume":"13","author":"Q Jin","year":"2008","unstructured":"Jin Q, Esteva FJ (2008) Cross-talk between the ErbB\/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer. J Mammary Gland Biol Neoplasia 13:485\u2013498","journal-title":"J Mammary Gland Biol Neoplasia"},{"key":"90_CR38","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1158\/0008-5472.CAN-08-0835","volume":"69","author":"F Huang","year":"2009","unstructured":"Huang F, Greer A, Hurlburt W et al (2009) The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR\/HER2 inhibitors. Cancer Res 69:161\u2013170","journal-title":"Cancer Res"},{"key":"90_CR39","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1159\/000178164","volume":"76","author":"D Takahari","year":"2009","unstructured":"Takahari D, Yamada Y, Okita NT et al (2009) Relationships of insulin-like growth factor-1 receptor and epidermal growth factor receptor expression to clinical outcomes in patients with colorectal cancer. Oncology 76:42\u201348","journal-title":"Oncology"},{"key":"90_CR40","doi-asserted-by":"publisher","first-page":"4291","DOI":"10.1158\/1078-0432.CCR-06-2040","volume":"13","author":"CJ Barnes","year":"2007","unstructured":"Barnes CJ, Ohshiro K, Rayala SK, El-Naggar AK, Kumar R (2007) Insulin-like growth factor receptor as a therapeutic target in head and neck cancer. Clin Cancer Res 13:4291\u20134299","journal-title":"Clin Cancer Res"},{"key":"90_CR41","doi-asserted-by":"crossref","first-page":"96","DOI":"10.7326\/0003-4819-82-1-96","volume":"82","author":"J Folkman","year":"1975","unstructured":"Folkman J (1975) Tumor angiogenesis: a possible control point in tumor growth. Ann Intern Med 82:96\u2013100","journal-title":"Ann Intern Med"},{"key":"90_CR42","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/nrc2458","volume":"8","author":"BR Zetter","year":"2008","unstructured":"Zetter BR (2008) The scientific contributions of M. Judah Folkman to cancer research. Nat Rev Cancer 8:647\u2013654","journal-title":"Nat Rev Cancer"},{"key":"90_CR43","doi-asserted-by":"publisher","first-page":"9277","DOI":"10.1158\/0008-5472.CAN-10-2029","volume":"70","author":"FE Escorcia","year":"2010","unstructured":"Escorcia FE, Henke E, McDevitt MR et al (2010) Selective killing of tumor neovasculature paradoxically improves chemotherapy delivery to tumors. Cancer Res 70:9277\u20139286","journal-title":"Cancer Res"},{"key":"90_CR44","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335\u20132342","journal-title":"N Engl J Med"},{"key":"90_CR45","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/nrc2442","volume":"8","author":"G Bergers","year":"2008","unstructured":"Bergers G, Hanahan D (2008) Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8:592\u2013603","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"90_CR46","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1056\/NEJMp1106984","volume":"365","author":"RB D'Agostino","year":"2011","unstructured":"D'Agostino RB (2011) Changing end points in breast-cancer drug approval\u2014the Avastin story. N Engl J Med 365(2):e2","journal-title":"N Engl J Med"},{"key":"90_CR47","doi-asserted-by":"crossref","unstructured":"Quinkler M, Kroiss M, Hahner S et al (2011) Sunitinib in refractory adrenocortical carcinoma: results of a phase II trial. Endocr Abstr (in press)","DOI":"10.1210\/endo-meetings.2011.PART2.OR4.OR13-1"},{"key":"90_CR48","doi-asserted-by":"publisher","first-page":"10090","DOI":"10.1158\/0008-5472.CAN-10-0489","volume":"70","author":"F Shojaei","year":"2010","unstructured":"Shojaei F, Lee JH, Simmons BH et al (2010) HGF\/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors. Cancer Res 70:10090\u201310100","journal-title":"Cancer Res"},{"key":"90_CR49","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nrc2594","volume":"9","author":"SC Smith","year":"2009","unstructured":"Smith SC, Theodorescu D (2009) Learning therapeutic lessons from metastasis suppressor proteins. Nat Rev Cancer 9:253\u2013264","journal-title":"Nat Rev Cancer"},{"key":"90_CR50","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.semcancer.2010.12.005","volume":"21","author":"LM Cook","year":"2011","unstructured":"Cook LM, Hurst DR, Welch DR (2011) Metastasis suppressors and the tumor microenvironment. Semin Cancer Biol 21:113\u2013122","journal-title":"Semin Cancer Biol"},{"key":"90_CR51","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/B978-0-12-385859-7.00003-3","volume":"286","author":"DR Hurst","year":"2011","unstructured":"Hurst DR, Welch DR (2011) Metastasis suppressor genes at the interface between the environment and tumor cell growth. Int Rev Cell Mol Biol 286:107\u2013180","journal-title":"Int Rev Cell Mol Biol"},{"key":"90_CR52","first-page":"87","volume":"1786","author":"M Iiizumi","year":"2008","unstructured":"Iiizumi M, Liu W, Pai SK, Furuta E, Watabe K (2008) Drug development against metastasis-related genes and their pathways: a rationale for cancer therapy. Biochim Biophys Acta 1786:87\u2013104","journal-title":"Biochim Biophys Acta"},{"key":"90_CR53","doi-asserted-by":"publisher","first-page":"9650","DOI":"10.1158\/0008-5472.CAN-10-1146","volume":"70","author":"Y Addadi","year":"2010","unstructured":"Addadi Y, Moskovits N, Granot D et al (2010) p53 status in stromal fibroblasts modulates tumor growth in an SDF1-dependent manner. Cancer Res 70:9650\u20139658","journal-title":"Cancer Res"},{"key":"90_CR54","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.ejso.2005.01.013","volume":"31","author":"S Sidhu","year":"2005","unstructured":"Sidhu S, Martin E, Gicquel C et al (2005) Mutation and methylation analysis of TP53 in adrenal carcinogenesis. Eur J Surg Oncol 31:549\u2013554","journal-title":"Eur J Surg Oncol"},{"key":"90_CR55","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1677\/ERC-08-0224","volume":"16","author":"CL Ronchi","year":"2009","unstructured":"Ronchi CL, Sbiera S, Kraus L et al (2009) Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy. Endocr Relat Cancer 16:907\u2013918","journal-title":"Endocr Relat Cancer"},{"key":"90_CR56","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1677\/erc.1.01025","volume":"12","author":"A Berruti","year":"2005","unstructured":"Berruti A, Terzolo M, Sperone P et al (2005) Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocr Relat Cancer 12:657\u2013666","journal-title":"Endocr Relat Cancer"},{"key":"90_CR57","doi-asserted-by":"crossref","unstructured":"Demeure MJ, Stephan E, Sinari S et al (2011) Preclinical investigation of nanoparticle albumin-bound paclitaxel as a potential treatment for adrenocortical cancer. Ann Surg (in press)","DOI":"10.1097\/SLA.0b013e3182402d21"},{"key":"90_CR58","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1159\/000007104","volume":"44","author":"F Fallo","year":"1998","unstructured":"Fallo F, Pilon C, Barzon L et al (1998) Paclitaxel is an effective antiproliferative agent on the human NCI-H295 adrenocortical carcinoma cell line. Chemotherapy 44:129\u2013134","journal-title":"Chemotherapy"},{"key":"90_CR59","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1158\/1535-7163.MCT-07-0267","volume":"7","author":"EA Stephan","year":"2008","unstructured":"Stephan EA, Chung TH, Grant CS et al (2008) Adrenocortical carcinoma survival rates correlated to genomic copy number variants. Mol Cancer Ther 7:425\u2013431","journal-title":"Mol Cancer Ther"},{"key":"90_CR60","doi-asserted-by":"publisher","first-page":"4233","DOI":"10.1038\/onc.2008.51","volume":"27","author":"G Eelen","year":"2008","unstructured":"Eelen G, Vanden Bempt I, Verlinden L et al (2008) Expression of the BRCA1-interacting protein Brip1\/BACH1\/FANCJ is driven by E2F and correlates with human breast cancer malignancy. Oncogene 27:4233\u20134241","journal-title":"Oncogene"},{"key":"90_CR61","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1210\/er.2009-0031","volume":"31","author":"L Ye","year":"2010","unstructured":"Ye L, Santarpia L, Gagel RF (2010) The evolving field of tyrosine kinase inhibitors in the treatment of endocrine tumors. Endocr Rev 31:578\u2013599","journal-title":"Endocr Rev"},{"key":"90_CR62","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/nrclinonc.2009.94","volume":"6","author":"HX Chen","year":"2009","unstructured":"Chen HX, Cleck JN (2009) Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 6:465\u2013477","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Hormones and Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-011-0090-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12672-011-0090-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-011-0090-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-011-0090-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T22:01:24Z","timestamp":1713218484000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12672-011-0090-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":62,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["90"],"URL":"https:\/\/doi.org\/10.1007\/s12672-011-0090-6","relation":{},"ISSN":["1868-8497","1868-8500"],"issn-type":[{"value":"1868-8497","type":"print"},{"value":"1868-8500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12]]},"assertion":[{"value":"15 December 2011","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}